Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 203M | 0% |
| Gross Profit | 170M | 10.3% |
| Cost of Revenue | 33M | 147.5% |
| Operating expense | 142M | 14.4% |
| Net Income | 13M | 16.2% |
| EBITDA | 50M | 3.8% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 1.32B | 1.8% |
| Total Liabilities | 676M | 5.4% |
| Total Equity | 643M | 1.7% |
| Shares Outstanding | 357M | 5.9% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 50M | 426.7% |
| Cash from investing | -18M | 64.7% |
| Cash from financing | -51M | 51.5% |
EPS
Financial Highlights for GoodRx in Q2 '25
GoodRx reported a revenue of 203M, which is a 0% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 170M, marking a -10.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 33M, a 147.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 142M, showing a -14.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 13M, showing a 16.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 50M, showing a 3.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
GoodRx faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
